Press Release: Phanes : Phanes Therapeutics Announces First Patient Dosed in Clinical Study of Peluntamig (PT217) in Combination with Chemotherapy

Phanes is a California-based biotechnology company that provides drug discovery, development and related services for the treatment of cancer and opthalmic diseases.